BioSpace News Archive

Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019

Corporate Restructuring and Pipeline Focus Expected to Extend Cash Runway

OvaScienceSM reported financial results for the second quarter ended June 30, 2018 and provided an update on its review of strategic alternatives.

AURORA Phase III Trial in lupus nephritis anticipated to complete enrollment ahead of schedule

Announced a Cooperative Research and Development Agreement (CRADA) to collaborate with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan (GMI-1271) in older, newly diagnosed acute myeloid leukemia (AML) patients eligible for intensive chemotherapy

Conference Call Today at 4:30 p.m. ET

Puma Biotechnology, Inc. announced financial results for the second quarter ended June 30, 2018.

Cigna Corporation issued the following letter to stockholders in response to the second letter released by Carl C. Icahn about the Company’s proposed merger with Express Scripts Holding Company

ARCA biopharma, Inc. reported financial results for the quarter ended June 30, 2018.

Kadmon Holdings, Inc. provided a business update and reported financial and operational results for the second quarter of 2018.